Healthcare / Medical Instruments & SuppliesNasdaqCM
$0.59
-0.01 (-1.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-3.9M · quality 60.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-67.3%
↓Gross Margin
39.5%
↓Debt/Equity
0.69
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-12.1%
FCF / Net income
0.46x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $11.4M · net income $-3.0M · FCF $-1.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | $11.4M | $11.4M | $8.7M | $4.1M | $2.0M | — | — | — | — |
| Net Income | $-3.0M | $-3.0M | $-3.3M | $-3.2M | $-4.7M | $-4.3M | $-2.3M | $-1.9M | $-1.9M |
| EBITDA | $-2.1M | $-2.1M | $-2.7M | $-2.7M | $-3.1M | $-2.5M | $-2.2M | $-1.9M | $-1.6M |
| EPS | — | — | -0.50 | -0.56 | -0.85 | -1.45 | -1.05 | -0.14 | -0.38 |
| Gross Margin | 39.5% | 39.5% | 31.6% | 9.1% | 12.5% | — | — | — | — |
| Operating Margin | -29.3% | -29.3% | -40.9% | -85.0% | -163.5% | — | — | — | — |
| Net Margin | -26.3% | -26.3% | -37.8% | -77.2% | -231.7% | — | — | — | — |
| Balance Sheet | |||||||||
| Debt/Equity | 0.69 | 0.69 | 0.49 | 0.60 | 0.27 | — | — | — | — |
| Current Ratio | 1.47 | 1.47 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-1.4M | $-1.4M | $-4.3M | $-3.9M | $-3.1M | $-3.0M | $-2.1M | $-1.8M | — |
| Returns | |||||||||
| ROE | -67.3% | -67.3% | -57.0% | -67.2% | -62.1% | -35.7% | -3188.7% | -506.1% | -671.9% |
| Valuation | |||||||||
| P/B | 1.08 | 1.08 | 4.33 | 2.81 | 0.99 | — | — | — | — |
| Growth & Yield | |||||||||
| Revenue Growth | 31.5% | 31.5% | 112.5% | 99.7% | — | — | — | — | — |
| EPS Growth | — | — | 10.7% | 34.1% | — | -38.1% | -650.0% | 63.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-72.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.50 → n/d
Residual
-72.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.